靶向对比剂CLT1-(Gd-DTPA)在小鼠乳腺癌磁共振分子成像效果的研究

本文研究了一个小肽靶向的对比剂CLT1-(Gd-DTPA) 对肿瘤基质中的纤维蛋白--链接纤维蛋白复和物的磁共振分子影像的效能.所用动物模型为带有MDA-MB-231乳腺癌的母系裸鼠,所用仪器为西门子3T磁共振成像仪,对比剂为Gd-(DTPA-BMA),所用CLT1-(Gd-DPTA)剂量为0.05 mmol/kg.该...

Evaluation of CLT1-(Gd-DTPA) for MR molecular imaging in a mouse breast cancer model

A peptide targeted contrast agent, CLT1-（Gd-DTPA）, was investigated for molecular imaging of fibrin-fribronectin complexes in tumor stroma with magnetic resonance imaging （MRI）. The contrast agent was evaluated in female nude mice bearing MDA-MB-231 human breast carcinoma xenografts on a Siemens 3T clinical scanner with a clinical agent Gd （DTPA-BMA） as a non-targeted control. CLT1-（Gd- DTPA） specifically bound to tumor tissue and resulted in significant tumor contrast enhancement at a dose of 0.05 mmol/kg for at least 60 minutes after injection. In contrast, a non-targeted contrast agent, Gd（DTPA-BMA）, cleared rapidly from the body with little tumor enhancement after 30 minutes post-injection at a dose of 0.1 mmol/kg. CLT1-（Gd-DTPA） had little non-specific binding in blood and normal tissues, including the liver and muscle, resulting in comparable non-specific enhancement in normal tissues to the control agent. The study has shown that CLT1- （Gd-DTPA） can bind to the tumor tissue, resulting in significant tumor enhancement in a mouse breast cancer model. The targeted contrast agent has a potential for MR molecular imaging of breast cancer.